Risk and protective factors for cognitive impairment in persons aged 85 years and older
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received September 3, 2014
- Accepted in final form December 18, 2014
- First Published April 8, 2015.
Article Versions
- Previous version (April 8, 2015 - 13:00).
- You are viewing the most recent version of this article.
Author Disclosures
- Rosebud O. Roberts, MB, ChB, MS,
- Ruth H. Cha, MS,
- Michelle M. Mielke, PhD,
- Yonas E. Geda, MD, MSc,
- Bradley F. Boeve, MD,
- Mary M. Machulda, PhD, LP,
- David S. Knopman, MD and
- Ronald C. Petersen, MD, PhD
- Rosebud O. Roberts, MB, ChB, MS,
NONE
NONE
NONE
Journal of Alzheimer's Disease; Associate Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH U01 AG006786 [Coinvestigator] 2009-2014
NONE
Mayo Clinic [coinvestigator], Driskill Foundation, and GHR Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Ruth H. Cha, MS,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Michelle M. Mielke, PhD,
NONE
NONE
I have received speaker honoraria from Eli Lilly and AbbVie.
Alzheimer's and Dementia: The Journal of the Alzheimer Association, associate editor, 2012-present Journal of Alzheimer Disease, associate editor, 2012-present
NONE
NONE
NONE
Eli Lilly and AbbVie
NONE
NONE
NONE
NONE
Dr. Mielke was funded by the following NIH grants: U01 AG037526 U01 AG006786
NONE
Dr. Mielke also received research support from the Walter S. and Lucienne B. Driskill Foundation which started in May 2012-present. Alzheimer drug discovery foundation. Role:PI. Date: 03/01/2013-present Michael J. Fox Foundation. Role: PI. Date: 01/01/2014-06/30/2015.
NONE
NONE
NONE
NONE
NONE
NONE
- Yonas E. Geda, MD, MSc,
NONE
NONE
NONE
2013 to present : Member, editorial board of International Psychogeriatrics.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
National Institutes of Health (NIH), K01 MH068531
NONE
1-Harold Amos Medical Faculty Development Award (RWJ foundation). 2- European Union Regional Development Fund (CZ.1.05/1.1.00/02.0123)
NONE
NONE
NONE
NONE
NONE
NONE
- Bradley F. Boeve, MD,
Tau Consortium
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
Grant support as an investigator in clinical trials funded by (1) Cephalon, Inc., 2009-2012, (2) Allon Therapeutics, Inc., 2010-2013; and (3) GE Healthcare, 2012-present.
National Institute on Aging [P50 AG016574 (2009-present), U01 AG006786 (2009-present), RO1 AG032306 (2010-present), RO1 AG041797 (2012-present) and UO1 AG045390 (2014- present)
NONE
Mangurian Foundation, 2011-present
NONE
NONE
NONE
NONE
NONE
NONE
- Mary M. Machulda, PhD, LP,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) National Institutes of Health; R01 DC 010367; Co- investigator 02/2010 - 01/2015 (2) Alzheimer's Association New Investigator Research Grant Co-Investigator 11/1/2012 - 10/31/2014 (3) National Institutes of Health; R01 DC 12519-01A1; Co- investigator 07/2013 - 06/2018 (4) Co-Investigator Core B - Clinical - Rochester in: Mayo Alzheimer's Disease Research Center. Funded by National Institute on Aging. (P50 AG 16574) 05/01/2014 - 04/30/2019
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David S. Knopman, MD and
Consultant Bluefield project (frontotemporal demantia); Lundbeck Pharmaceuticals (Sept 2013 ongoing); DIAN study DSMB (Sept 2013 ongoing).
NONE
(1) Lecture, University of Pennsylvania, January 2013 (2) Lecture, St Johns Hospital, Jackson Hole Wyoming June 2013 (3) Lecture, Amer Soc Neuroradiol, San Diego CA, May 2013 (4) Lectures, Alzheimer Conference, Seoul Korea, December 2014
Neurology, Deputy Editor
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Tau Rx clinical trial
NIH: R01-AG11378 ongoing, P50-AG 16574 (Mayo Alzheimer?s Disease Research Center) ongoing, U01 AG 06786 (Mayo Alzheimer Disease Patient Registry) ongoing. 1U01HL096917-01 ARIC Dementia Study. AG 037551 Chronic Kidney Disease and Cognitive functioning.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Ronald C. Petersen, MD, PhD
(1) Pfizer, Inc., Chair, Data Monitoring Committee; (2) Janssen Alzheimer Immunotherapy, Chair, Data Monitoring Committee
NONE
NONE
NONE
NONE
Mild Cognitive Impairment,Oxford University Press, 2003
NONE
(1) Roche Incorporated, (2) Merck, (3) Genentech
NONE
NONE
NONE
NONE
National Institute on Aging: U01-AG006786 (PI) (1986-present) P50-AG016574 (PI) (1990-present) R01-AG011378 (Co-I) U01-AG024904 (Co-I) Non-financial disclosures: National Advisory Council on Aging, National Institute on Aging
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Divisions of Epidemiology (R.O.R., M.M. Mielke, Y.E.G., R.C.P.) and Biomedical Statistics and Informatics (R.H.C.), Department of Health Sciences Research, the Department of Neurology (R.O.R., B.F.B., D.S.K., R.C.P.), and the Department of Psychiatry and Psychology (M.M. Machulda), Mayo Clinic, Rochester, MN; and the Departments of Psychiatry and Psychology and Neurology (Y.E.G.), Mayo Clinic, Scottsdale, AZ.
- Correspondence to Dr. Roberts: roberts.rosebud{at}mayo.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
NOTE: All authors' disclosures must be entered and current in our database before comments can be posted. Enter and update disclosures at http://submit.neurology.org. Exception: replies to comments concerning an article you originally authored do not require updated disclosures.
- Stay timely. Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- 200 words maximum.
- 5 references maximum. Reference 1 must be the article on which you are commenting.
- 5 authors maximum. Exception: replies can include all original authors of the article.
- Submitted comments are subject to editing and editor review prior to posting.